Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens.

Kasai M, Ichimura T, Kawamura N, Sumikura T, Matsuda M, Asano C, Sumi T, Ishiko O.

Fertil Steril. 2012 Aug;98(2):440-3. doi: 10.1016/j.fertnstert.2012.05.013. Epub 2012 Jun 29.

PMID:
22749217
2.

Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment.

Kawamura N, Ito F, Ichimura T, Shibata S, Umesaki N, Ogita S.

Fertil Steril. 1997 Oct;68(4):632-6.

PMID:
9341601
3.

Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens.

Ichimura T, Kawamura N, Ito F, Shibata S, Minakuchi K, Tsujimura A, Umesaki N, Ogita S.

Fertil Steril. 1998 Nov;70(5):967-71.

PMID:
9806586
4.

Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.

Ito F, Kawamura N, Ichimura T, Tsujimura A, Ishiko O, Ogita S.

Fertil Steril. 2001 Jan;75(1):125-30.

PMID:
11163826
6.

A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.

Baytur YB, Ozbilgin K, Cilaker S, Lacin S, Kurtul O, Oruc S, Koyuncu FM.

Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. Epub 2006 Sep 14.

PMID:
16973256
7.
9.
10.

Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.

Fernández-Montolí ME, Díez-Gibert O, Samaniego JM, Balagueró L, Navarro MA.

Fertil Steril. 1995 Mar;63(3):522-7.

PMID:
7851581
11.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.

Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH.

Fertil Steril. 2010 Jan;93(1):192-8. doi: 10.1016/j.fertnstert.2008.09.064. Epub 2009 Jan 9.

PMID:
19135657
12.

Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.

Uemura T, Mori J, Yoshimura Y, Minaguchi H.

Asia Oceania J Obstet Gynaecol. 1991 Dec;17(4):315-20.

PMID:
1724899
13.
14.

Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.

Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Doldo P, Nappi C, Lombardi G, Mastrantonio P, Zullo F.

Hum Reprod. 2004 Jun;19(6):1308-14. Epub 2004 Apr 29.

PMID:
15117890
15.

Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.

Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Lombardi G, Cimini V, Zullo F.

Fertil Steril. 2005 Jul;84(1):154-61.

PMID:
16009171
16.

[Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma].

Kurose T, Hando T, Shiota A.

Nihon Sanka Fujinka Gakkai Zasshi. 1995 Jan;47(1):35-41. Japanese.

PMID:
7844451
17.

Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin.

Ueki M, Okamoto Y, Tsurunaga T, Seiki Y, Ueda M, Sugimoto O.

J Obstet Gynaecol (Tokyo 1995). 1995 Feb;21(1):1-7.

PMID:
8591104
18.

Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.

Palomba S, Morelli M, Di Carlo C, Noia R, Pellicano M, Zullo F.

Fertil Steril. 2002 Jul;78(1):63-8.

PMID:
12095492
19.

Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women.

Vollenhoven BJ, Pearce P, Herington AC, Healy DL.

Clin Endocrinol (Oxf). 1994 Apr;40(4):537-44.

PMID:
8187322
20.

Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.

De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A.

J Soc Gynecol Investig. 2006 May;13(4):297-303.

PMID:
16697947

Supplemental Content

Support Center